ABI-009
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABI-009, covering 2021-06-08 to 2021-06-10. Get the full timeline:
Most recent: Clinical Trial Update: A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System [Phase 2]